Naomitsu Watanabe, MD
Internal Medicine · Milford, DENPI 1821542895
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 178 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,732 and has fallen 96.8% since, to $56 in 2025.
Across 178 payments — averaging $23.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$952
- AstraZeneca$652
- Novo Nordisk$394
- Amgen$247
- Lilly USA, LLC$184
- Bayer$175
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,164100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 39 | $952 |
| AstraZeneca | 29 | $652 |
| Novo Nordisk | 22 | $394 |
| Amgen(2 entities) | 8 | $247 |
| Lilly USA, LLC | 9 | $184 |
| Bayer | 8 | $175 |
| AbbVie | 7 | $157 |
| Sumitomo Pharma America, Inc. | 3 | $151 |
| Boehringer Ingelheim | 5 | $144 |
| Lundbeck LLC | 6 | $126 |
| Corcept Therapeutics | 6 | $114 |
| Xeris Pharmaceuticals, Inc. | 1 | $113 |
| Abbott | 5 | $100 |
| Dexcom, Inc. | 4 | $81 |
| Merck | 3 | $78 |
| Pfizer | 4 | $75 |
| Exact Sciences | 2 | $52 |
| Biohaven Pharmaceuticals, Inc. | 2 | $43 |
| Neurocrine Biosciences, Inc. | 2 | $42 |
| Embecta Corp. | 1 | $41 |
| Seqirus USA Inc | 2 | $41 |
| Sunovion Pharmaceuticals Inc. | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| BD | 1 | $29 |
| EMD Serono, Inc. | 1 | $24 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$242
- TEZSPIRE$135
- GVOKE HYPOPEN$113
- GEMTESA$110
- KRYSTEXXA$110
How this compares
$4,164 in reported general payments places this provider in the 85th percentile of 477 internal medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $63,279 |
| EliquisApixaban | 47 | $49,150 |
| JardianceEmpagliflozin | 36 | $42,878 |
| RybelsusSemaglutide | 18 | $39,711 |
| FarxigaDapagliflozin Propanediol | 38 | $35,651 |
| OzempicSemaglutide | 27 | $34,320 |
| MounjaroTirzepatide | 17 | $25,805 |
| TradjentaLinagliptin | 17 | $15,255 |
| LinzessLinaclotide | 14 | $15,219 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $13,627 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $10,090 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $9,072 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 105 | $4,514 |
| Atorvastatin Calcium | 273 | $2,693 |
| Nifedipine ErNifedipine | 44 | $1,586 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $952 | $82,44176 claims |
| Novo NordiskRybelsus, Ozempic | $394 | $74,03145 claims |
| Boehringer IngelheimJardiance, Tradjenta | $144 | $58,13353 claims |
| PfizerEliquis | $75 | $49,15047 claims |
| AstraZenecaFarxiga | $652 | $35,65138 claims |
| Lilly USA, LLCMounjaro | $184 | $25,80517 claims |
| AbbVieLinzess | $157 | $15,21914 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $36 | $13,62712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 477 internal medicine providers in Delaware.
Other internal medicine in Milford
- Seth IvinsNewark$384K
- Beshara HelouGeorgetown$143K
- Tabassum SalamNewark$62K
- Fabricio AlarconGeorgetown$30K
- Jose CastroWilmington$27K
- Marcia Gina CastroWilmington$24K
- Bhaskar PalekarLewes$22K
- Fadi DamouniMillsboro$17K
- Rene BadilloBear$16K
- Robert KopeckiWilmington$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.